Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Fierce Pharma14h
Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
What is HC Wainwright’s Forecast for Zymeworks Q1 Earnings?
Investment analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for Zymeworks in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates ...